Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.
about
Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United StatesDrug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An OverviewDrug-induced hepatotoxicity: metabolic, genetic and immunological basisAlcoholic and non-alcoholic steatohepatitisPharmGKB summary: very important pharmacogene information for N-acetyltransferase 2Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Isoniazid metabolism and hepatotoxicityAnti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patientsIncidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in ChinaPharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysisCytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohortEnhancement of CYP3A4 activity in Hep G2 cells by lentiviral transfection of hepatocyte nuclear factor-1 alphaThe incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1Mechanism of isoniazidāinduced hepatotoxicity: then and nowAntitubercular therapy in patients with cirrhosis: challenges and optionsPharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012.Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol)Drug-induced liver injury in older adults.Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.Epidemiology and risk factors for drug allergy.Pharmacogenomics of antimicrobial agents.Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan populationAge-related changes in the hepatic pharmacology and toxicology of paracetamol.Risk factors for idiosyncratic drug-induced liver injury.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Pharmacogenetics of isoniazid-induced hepatotoxicity.Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS.Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health TransitionIdiosyncratic drug hepatotoxicity.Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteersAntioxidant, Hepatoprotective Potential and Chemical Profiling of Propolis Ethanolic Extract from Kashmir Himalaya Region Using UHPLC-DAD-QToF-MS.Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?Hepatoprotective Activity of Heptoplus on Isoniazid and Rifampicin Induced Liver Damage in Rats.Role of pharmacogenomics in the treatment of tuberculosis: a review
P2860
Q26767296-589721C3-F089-4D02-9230-3E9AF806F06EQ26767516-688228B9-85A4-4F67-A771-8AFF53CF2C3FQ26991809-39BFFF4F-BB82-4C93-9B08-4EC82B8CF81EQ27000153-172ACB16-F12C-45D9-968B-96DD4AFFF825Q27011622-A4E631F0-C5F3-4717-B63A-88CF39B2FB73Q27690772-E0FD533D-67AC-45E6-9192-67201DF56602Q28076859-55DBE5F8-D470-4BF1-9C69-43F7816C5447Q28472348-4DDE701A-AE99-4451-8DE2-8760102AA867Q28478918-F4FD06FB-124D-4EB0-BDC6-093EA149BD9AQ28484468-2C734F45-55F2-4920-9E15-01E85A302258Q28486869-99B2A019-35E6-49C4-BE61-484B07CA1E2EQ28537869-C4A434D0-651A-412C-81BA-66DC0F9BB73EQ28539060-40E0E3FF-BC89-4873-9DE7-ABF947517AFFQ29248263-58B67F42-EF48-4E87-88BE-BD9034EE9899Q33626827-63A7F595-9510-442C-B587-66ABFFD51E82Q33797850-D146BCCF-EB25-497C-80F7-E2E8FE29608BQ33813166-0199F6BF-2F0D-4C55-971A-B43D5487BC50Q33901424-CBC4C87A-3E08-4A1B-B249-8712A9C05437Q33949227-B1DA3A07-5408-421B-BE29-F1591506A81DQ34273450-5B64A0B9-68F2-44C9-A76F-10FD79115D09Q34606196-17660F89-ABE2-4450-8FA0-048175B8B159Q34976470-8F1B1169-73D1-44DD-B25A-30F35BA84F52Q34977413-24A6AB15-1AB2-47A7-A404-4AF4E426FCB6Q34986858-AB2840A2-1E10-4D34-89B5-91F2DF2B151AQ35101500-BDFE1EDA-BBD8-4263-AB5F-36A73AD02387Q35168108-F4EF5E0C-DA85-446E-86DE-8C6592DAFF3BQ35617587-CEE7FC00-7DB1-4A4D-9346-17B95758E55CQ35669887-6E36E6B8-CF33-448B-AE41-187A7EAA3E13Q35873687-9F566A6F-3287-4E4B-AC01-60E4E9670272Q35934555-C89ED7B0-7C34-4B2D-9EF9-6EE28F7F8832Q36040772-9631C300-69F9-4D3C-A539-8884ACD8E23CQ36058879-005A59F8-14A5-4F0D-BC45-8E084BEDF1E7Q36105822-E1F72643-B372-4EF0-922D-BB42C70AC02CQ36148442-D1F2C596-E089-49C6-8AC6-E04C4731FF56Q36158322-DB8EDA2C-EFC1-4D3D-95DE-E199C7CCAC51Q36204077-C866B44A-B58A-43D7-92B9-752C385836FAQ36362377-35F1CF98-B684-4BFB-BE2C-78A0E78465D6Q36368104-93D9A475-66A7-40F9-8D55-3BD59EAD6BA5Q36428771-22ED3825-924A-426E-973A-7FE9A62A863AQ36441540-12BEE4BD-56AB-4F52-90C9-52D58B7FC612
P2860
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.
description
2003 nĆ® lÅ«n-bĆ»n
@nan
2003幓ć®č«ę
@ja
2003幓å¦ęÆęē«
@wuu
2003幓å¦ęÆęē«
@zh
2003幓å¦ęÆęē«
@zh-cn
2003幓å¦ęÆęē«
@zh-hans
2003幓å¦ęÆęē«
@zh-my
2003幓å¦ęÆęē«
@zh-sg
2003幓åøč”ęē«
@yue
2003幓åøč”ęē«
@zh-hant
name
Cytochrome P450 2E1 genotype a ...... ulosis drug-induced hepatitis.
@en
Cytochrome P450 2E1 genotype a ...... ulosis drug-induced hepatitis.
@nl
type
label
Cytochrome P450 2E1 genotype a ...... ulosis drug-induced hepatitis.
@en
Cytochrome P450 2E1 genotype a ...... ulosis drug-induced hepatitis.
@nl
prefLabel
Cytochrome P450 2E1 genotype a ...... ulosis drug-induced hepatitis.
@en
Cytochrome P450 2E1 genotype a ...... ulosis drug-induced hepatitis.
@nl
P2093
P356
P1433
P1476
Cytochrome P450 2E1 genotype a ...... ulosis drug-induced hepatitis.
@en
P2093
Chi-Huei Chiang
Full-Young Chang
Herng-Der Chern
Jaw-Ching Wu
Shi-Chuan Chang
Shou-Dong Lee
Wei-Juin Su
Yi-Shin Huang
P304
P356
10.1053/JHEP.2003.50144
P407
P577
2003-04-01T00:00:00Z